Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
U.S. Congress. House. To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. H.R. 1051. 119th Cong., 1st sess., Introduced in House February 6, 2025. https://www.govinfo.gov/app/details/BILLS-119hr1051ih.
Congress, House of Representatives (2025, February 6). To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. (H.R. 1051 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119hr1051ih.
United States, Congress, House of Representatives. To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119hr1051ih. 119th Congress, H.R. 1051, Introduced in House 6 Feb. 2025.
H.R.1051 - 119th Congress (2025-2026): To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes., H.R.1051, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119hr1051ih.